MedRx (4586) Stock Overview
A pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4586 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MedRx Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥85.00 |
| 52 Week High | JP¥225.00 |
| 52 Week Low | JP¥58.00 |
| Beta | 0.67 |
| 1 Month Change | -21.30% |
| 3 Month Change | -27.35% |
| 1 Year Change | 32.81% |
| 3 Year Change | -43.71% |
| 5 Year Change | -64.44% |
| Change since IPO | -96.30% |
Recent News & Updates
Shareholder Returns
| 4586 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 1.2% | 1.6% | 1.5% |
| 1Y | 32.8% | 23.4% | 47.1% |
Return vs Industry: 4586 exceeded the JP Pharmaceuticals industry which returned 23.4% over the past year.
Return vs Market: 4586 underperformed the JP Market which returned 47.1% over the past year.
Price Volatility
| 4586 volatility | |
|---|---|
| 4586 Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4586's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4586's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 21 | Yonehiro Matsumura | www.medrx.co.jp |
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain.
MedRx Co., Ltd Fundamentals Summary
| 4586 fundamental statistics | |
|---|---|
| Market cap | JP¥5.11b |
| Earnings (TTM) | -JP¥937.00m |
| Revenue (TTM) | JP¥128.00m |
Is 4586 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4586 income statement (TTM) | |
|---|---|
| Revenue | JP¥128.00m |
| Cost of Revenue | JP¥2.00m |
| Gross Profit | JP¥126.00m |
| Other Expenses | JP¥1.06b |
| Earnings | -JP¥937.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.78 |
| Gross Margin | 98.44% |
| Net Profit Margin | -732.03% |
| Debt/Equity Ratio | 0% |
How did 4586 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/21 12:22 |
| End of Day Share Price | 2026/04/21 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedRx Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Dion Stéfan Büchner | Pathology Associates Co., Ltd. |